Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial (2019)

Peer-Reviewed Study · Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM · May 10, 2019

Rosenthal SA et al., 2019-05-10: RTOG 0521 randomised 563 evaluable men with high-risk non-metastatic prostate cancer to androgen suppression plus radiotherapy with or without six cycles of adjuvant docetaxel. Four-year overall survival was 89% vs 93% (HR 0.69, one-sided P=.034), with fewer distant metastases at six years (9.1% vs 14%).

Four-year OS rate was 89% (95% CI, 84% to 92%) for AS + RT and 93% (95% CI, 90% to 96%) for AS + RT + CT (hazard ratio [HR], 0.69; 90% CI, 0.49 to 0.97; one-sided P = .034).

Abstract (RESULTS)

Rosenthal SA et al., 2019-05-10: RTOG 0521 randomised 563 evaluable men with high-risk non-metastatic prostate cancer to androgen suppression plus radiotherapy with or without six cycles of adjuvant docetaxel. Four-year overall survival was 89% vs 93% (HR 0.69, one-sided P=.034), with fewer distant metastases at six years (9.1% vs 14%). Funder: trial run by NRG Oncology/RTOG under NCI cooperative group mechanisms; the JCO funding and disclosure appendix could not be retrieved (PMC page returned no text in this run) – verifier should pull the JCO PDF. Maker: Sanofi (docetaxel). Comparator: androgen suppression plus radiotherapy alone. This is chemotherapy added to radiotherapy, not chemotherapy alone, and the survival result rests on a one-sided test with a 90% CI. Study type: randomized trial.